ZA202003310B - Poly-adp ribose polymerase (parp) inhibitors - Google Patents
Poly-adp ribose polymerase (parp) inhibitorsInfo
- Publication number
- ZA202003310B ZA202003310B ZA2020/03310A ZA202003310A ZA202003310B ZA 202003310 B ZA202003310 B ZA 202003310B ZA 2020/03310 A ZA2020/03310 A ZA 2020/03310A ZA 202003310 A ZA202003310 A ZA 202003310A ZA 202003310 B ZA202003310 B ZA 202003310B
- Authority
- ZA
- South Africa
- Prior art keywords
- parp
- inhibitors
- poly
- ribose polymerase
- adp ribose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202003310B true ZA202003310B (en) | 2021-08-25 |
Family
ID=61007849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/04004A ZA201904004B (en) | 2016-12-30 | 2019-06-20 | Poly-adp ribose polymerase (parp) inhibitors |
| ZA2020/03310A ZA202003310B (en) | 2016-12-30 | 2020-06-03 | Poly-adp ribose polymerase (parp) inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/04004A ZA201904004B (en) | 2016-12-30 | 2019-06-20 | Poly-adp ribose polymerase (parp) inhibitors |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US11034670B2 (en) |
| EP (1) | EP3562822B1 (en) |
| JP (1) | JP7141399B2 (en) |
| KR (1) | KR102606799B1 (en) |
| CN (1) | CN110167926B (en) |
| AR (1) | AR110706A1 (en) |
| AU (1) | AU2017388376B2 (en) |
| BR (1) | BR112019011676A2 (en) |
| CA (1) | CA3047137A1 (en) |
| CO (1) | CO2019007906A2 (en) |
| CY (1) | CY1124565T1 (en) |
| DK (1) | DK3562822T3 (en) |
| EA (1) | EA201991412A1 (en) |
| ES (1) | ES2875841T3 (en) |
| HR (1) | HRP20210887T1 (en) |
| HU (1) | HUE054382T2 (en) |
| IL (1) | IL267676B (en) |
| JO (1) | JOP20190115B1 (en) |
| LT (1) | LT3562822T (en) |
| MA (1) | MA47165B1 (en) |
| MD (1) | MD3562822T2 (en) |
| MX (1) | MX2019007870A (en) |
| PH (1) | PH12019501529A1 (en) |
| PL (1) | PL3562822T3 (en) |
| PT (1) | PT3562822T (en) |
| RS (1) | RS61895B1 (en) |
| SA (1) | SA519401894B1 (en) |
| SI (1) | SI3562822T1 (en) |
| TW (1) | TWI773718B (en) |
| UA (1) | UA124777C2 (en) |
| WO (1) | WO2018125961A1 (en) |
| ZA (2) | ZA201904004B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3562822T3 (en) * | 2016-12-30 | 2021-05-03 | Mitokyne Inc | Poly-adp ribose polymerase (parp) inhibitors |
| CA3158807A1 (en) * | 2019-10-30 | 2021-05-06 | Digmbio. Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| KR20240057402A (en) * | 2021-07-23 | 2024-05-02 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | Gram-negative bacterial efflux pump inhibitor |
| CN113603630B (en) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | Synthesis method of 4-phenylpiperidine hydrochloride |
| WO2024061768A1 (en) | 2022-09-19 | 2024-03-28 | Basf Se | Azole pesticidal compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070737A2 (en) | 2000-03-20 | 2001-09-27 | Sepracor, Inc. | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof |
| US20030087917A1 (en) | 2000-03-27 | 2003-05-08 | Dorothea Strack | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CN1922171B (en) | 2004-02-26 | 2012-10-17 | Aska制药株式会社 | Pyrimidine derivative |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | Compound having s1p receptor binding potency and use thereof |
| CA2569826C (en) * | 2004-06-30 | 2013-07-16 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| JP2009501235A (en) | 2005-07-15 | 2009-01-15 | シェーリング コーポレイション | Quinazoline derivatives useful in cancer treatment |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EP2010505B1 (en) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN103298474B (en) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | Heterocyclic compound and application thereof |
| EP2697206B1 (en) | 2011-04-10 | 2019-04-03 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (en) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | Phenylquinazoline PI3Kdelta inhibitors |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| BR112016001645B1 (en) | 2013-07-31 | 2023-04-11 | Merck Patent Gmbh | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES, THEIR USE, MEDICINES |
| CA2948067A1 (en) | 2014-05-07 | 2015-11-12 | Merck Patent Gmbh | Heterocyclyl-butanamide derivatives |
| CN105924434A (en) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | Substituted aminopyrimidine compound and usage method and application thereof |
| US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
| DK3562822T3 (en) * | 2016-12-30 | 2021-05-03 | Mitokyne Inc | Poly-adp ribose polymerase (parp) inhibitors |
-
2017
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/en active
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/en active Active
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/en unknown
- 2017-12-28 RS RS20210653A patent/RS61895B1/en unknown
- 2017-12-28 PT PT178326948T patent/PT3562822T/en unknown
- 2017-12-28 SI SI201730772T patent/SI3562822T1/en unknown
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 BR BR112019011676A patent/BR112019011676A2/en unknown
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/en unknown
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/en active IP Right Grant
- 2017-12-28 UA UAA201908940A patent/UA124777C2/en unknown
- 2017-12-28 MA MA47165A patent/MA47165B1/en unknown
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 MX MX2019007870A patent/MX2019007870A/en unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en active Search and Examination
- 2017-12-28 PL PL17832694T patent/PL3562822T3/en unknown
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/en unknown
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/en active Active
- 2017-12-28 ES ES17832694T patent/ES2875841T3/en active Active
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/en active
- 2017-12-28 EA EA201991412A patent/EA201991412A1/en unknown
- 2017-12-29 TW TW106146555A patent/TWI773718B/en active
- 2017-12-29 AR ARP170103718A patent/AR110706A1/en unknown
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/en unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/en unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-04 HR HRP20210887TT patent/HRP20210887T1/en unknown
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/en unknown
- 2021-06-09 US US17/342,873 patent/US11993585B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| HK1255269A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| ZA201704293B (en) | Selective bace1 inhibitors | |
| ZA202003310B (en) | Poly-adp ribose polymerase (parp) inhibitors | |
| GB201615282D0 (en) | Tankyrase inhibitors | |
| IL268955B (en) | Selective hdac6 inhibitors | |
| HK1257568A1 (en) | Inflammasome activation inhibitor | |
| MA43367A (en) | METALLO-BETA-LACTAMASES INHIBITORS | |
| GB2544132B (en) | Inhibitors that enhance insecticide performance | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| EP3244735A4 (en) | Improved pathogen inhibitor | |
| GB201612860D0 (en) | Inhibitors | |
| ZA201901773B (en) | Pde4 inhibitor | |
| EP3484854A4 (en) | Apoptosis inhibitors | |
| GB201505658D0 (en) | Inhibitor compounds | |
| GB201501004D0 (en) | Inhibitors | |
| HK1251572A1 (en) | Triaza-spirodecanones as ddr1 inhibitors | |
| EP3288712C0 (en) | Device for machining surfaces | |
| HK1244790A1 (en) | Bace1 inhibitors | |
| IL247025A0 (en) | Enzyme inhibitors | |
| GB201520949D0 (en) | Inhibitors | |
| HK1245250A1 (en) | Targeted notch pathway inhibitors | |
| GB201614783D0 (en) | Kinases inhibitors | |
| EP3335694A4 (en) | Melanogenesis inhibitor |